Mechanisms of Endocrine Resistance in Breast Cancer
Top Cited Papers
- 18 February 2011
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 62 (1), 233-247
- https://doi.org/10.1146/annurev-med-070909-182917
Abstract
The estrogen receptor (ER) pathway plays a pivotal role in breast cancer development and progression. Endocrine therapy to block the ER pathway is highly effective, but its usefulness is limited by common intrinsic and acquired resistance. Multiple mechanisms responsible for endocrine resistance have been proposed and include deregulation of various components of the ER pathway itself, alterations in cell cycle and cell survival signaling molecules, and the activation of escape pathways that can provide tumors with alternative proliferative and survival stimuli. Among these, increased expression or signaling of growth factor receptor pathways, especially the EGFR/HER2 pathway, has been associated with both experimental and clinical endocrine therapy resistance. New treatment combinations targeting both ER and growth factor receptor signaling to block the crosstalk between these pathways and eliminate escape routes have been proven highly effective in preclinical models. Results of recent clinical studies, while partly supporting this approach, also highlight the need to better identify a priori the patients whose tumors are most likely to benefit from these specific cotargeting strategies.Keywords
This publication has 91 references indexed in Scilit:
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cellsBreast Cancer Research and Treatment, 2009
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2009
- Estrogen receptors outside the nucleus in breast cancerBreast Cancer Research and Treatment, 2007
- Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancerSteroids, 2007
- A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancerProceedings of the National Academy of Sciences of the United States of America, 2006
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Endocrine-responsive breast cancer and strategies for combating resistanceNature Reviews Cancer, 2002